Ben Kowalski is a writer and researcher who covers men's health, sexual wellness, and online healthcare services. He stumbled into health writing after realizing how much bad information exists online about topics men are too embarrassed to ask their doctor about. Ben thinks that needs to change. When he is not untangling medical jargon or stress-testing telehealth apps, he is watching Premier League football, grilling something, or losing at trivia nights with the same group of friends he has had since college.
How we scoreOur 1 to 10 brand scores are our own editorial judgment. They are not aggregated from third-party review platforms and they are not the output of a scoring formula.
What a starting price isA starting price is the lowest figure a company lists for a category, not a quote. What you pay follows a clinician's review of your intake, and where a required membership or care plan sits alongside the medication we publish the two charges combined.
Reading a warning letterA close-out letter is FDA's record that it has evaluated a company's corrective actions, so the absence of one means the file is not closed on the public record, and nothing more than that.
Regulatory noticeRegulatory note (verified October 8, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. The letter also quotes three claims from the site, among them "Generic Zepbound, Mounjaro", along with site copy naming semaglutide and tirzepatide as the active ingredient in the brand medications. Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. The letter adds that introducing or delivering the products it identifies into interstate commerce is a prohibited act under section 301(a), that receiving them in interstate commerce and delivering or offering to deliver them also violates section 301(c), and that a compounded drug product must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements, including the new drug approval requirements. When we checked FDA's warning letter index for Strut Health, LLC on October 8, 2026 it showed no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): A May 2026 review of maximustribe.com led the FDA to issue Maximus Health, Inc. warning letter MARCS-CMS 730095 on June 8, 2026. The language quoted here concerns effect and sourcing rather than ingredient comparison: "Clinically studied ingredients," "Clinically studied to help patients...," and "Proven to lose weight effectively," alongside a statement that the compounded products come from "FDA approved pharmacies." On that last point the agency was explicit that no FDA-approved or FDA-licensed designation exists for compounding pharmacies or outsourcing facilities, so describing one that way is misleading. Both findings were cited as misbranding under FD&C Act 502(a) and 502(bb). Nothing in FDA’s index records a close-out, so we log the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified October 31, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. The letter cites two lines of Hims marketing for compounded semaglutide: one presenting it as having the same active ingredient as Ozempic and Wegovy, and one making a clinical-evidence claim for its ingredients. Compounded drug products are not FDA-approved, and the agency’s position is that phrasing of this sort suggests otherwise, which in its view makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. When we checked FDA’s warning letter index on November 14, 2026 it showed no response letter and no close-out letter, so treat this as open. Read the FDA letter